Modulation of human chondrocyte metabolism by recombinant human interferon  by Henrotin, Y.E et al.
Osteoarthritis and Cartilage (2000) 8, 474–482
© 2000 OsteoArthritis Research Society International 1063–4584/00/060474+09 $35.00/0
doi:10.1053/joca.2000.0323, available online at http://www.idealibrary.com onModulation of human chondrocyte metabolism by recombinant human
interferon
Y. E. Henrotin*, S. X. Zheng*, A. H. Labasse*, G. P. Deby†, J-M. R. Crielaard* and
J-Y. L. Reginster*
*Bone and Cartilage Metabolism Research Unit, University Hospital, CHU Sart-Tilman, 4000 Lie`ge, Belgium
†Center for Oxygen Research and Development, Institute of Chemistry, University of Lie`ge, Sart-Tilman,
4000 Lie`ge, Belgium
Summary
Objectives: Interferon gamma (IFN) is found to be elevated in the synovial fluid of patients with rheumatoid arthritis and osteoarthritis,
suggesting its implication in joint disease pathogenesis. In this study, we investigated the effects of IFN on the production of cytokines (IL-6,
IL-8, IL-10), prostaglandin E2 (PGE2), proteoglycans (PG), nitric oxide (NO), interleukin-1 receptor antagonist (IL-1ra) and stromelysin by
non-stimulated and IL-1-treated human chondrocytes. The role played by NO in the responses of chondrocytes to IFN was also examined
by incubation of chondrocytes with NG-monomethyl-L-arginine (L-NMMA), a competitive inhibitor of NO synthase.
Methods: Enzymatically isolated human chondrocytes were cultured for 48 h in the absence or presence of IL-1, IFN or NG-monomethyl-
L-arginine (L-NMMA) added solely or in combination. The productions of IL-6, IL-8, IL-10, IL-1ra and stromelysin were measured by enzyme
amplified sensitivity immunoassays (EASIA). PG and PGE2 were quantified by specific radioimmunoassays (RIA). Nitrite concentrations in
the culture supernatants were determined by a spectrophotometric method based upon the Griess reaction.
Results: As expected, IL-1 highly stimulated NO, IL-6, IL-8, IL-10, IL-1ra, PGE2 and stromelysin synthesis, but dramatically decreased PG
production. NO, IL-6, IL-1ra and PGE2 production by non-stimulated chondrocytes was dose-dependently increased by IFN while PG
production was inhibited. In the absence of IL-1, IL-10 was undetectable in the culture supernatants. At the doses of 10 and 100 U/ml, IFN
markedly inhibited the constitutive and IL-1-stimulated IL-8, IL-10 and stromelysin productions. Interestingly, IFN synergized with IL-1 to
increase NO, IL-6, IL-1ra and to depress PG production. As previously reported, the inhibition of NO synthesis by the competitive inhibitor
L-NMMA led to enhancement of IL-6, IL-8 and PGE2 production by IL-1 treated chondrocytes, but did not significantly modify IL-10, PG and
MMP-3 productions. Inhibition of NO synthase significantly inhibited the stimulating effect of IFN on IL-6 and IL-1ra but did not affect the
inhibitory effect of IFN on IL-8, PG or stromelysin production.
Conclusions: These findings suggest that IFN and IL-1 synergistically stimulate the production of IL-6, IL-1ra, NO and PGE2 and inhibit PG
synthesis. By contrast, IL-1 and IFN have opposite effects on IL-8, IL-10 and stromelysin productions. These effects are not reversed by
L-NMMA, suggesting that NO is not the principal mediator involved in responses of chondrocytes to IFN. © 2000 OsteoArthritis Research
Society International
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The role of interferon gamma (IFN) in the pathogenesis of
inflammatory joint diseases and the accompanying
destruction of cartilage and other joint tissues remains
poorly defined. IFN was found to be elevated in synovial
fluid and sera of patients with rheumatoid arthritis and
osteoarthritis (OA), suggesting a direct implication of this
cytokine in joint disease pathophysiology.1,2 Moreover, the
presence of activated T-cells and Th1 cytokine transcripts
in the synovial membrane of patients with OA suggests that
T-cells and, thus, IFN, contribute to chronic inflammation
in a large proportion of these patients.3474At this time, divergent in vitro and in vivo results have
been reported in the literature. When administered by
systemic injection in a polyarthritis model induced by injec-
tion of peptidoglycan-polysaccharide (PG-APS), IFN sup-
pressed the severity of acute and chronic erosive
polyarthritis.4,5 This effect was associated with a marked
reduction in the number of neutrophils and monocytes
infiltrating the tissue, and correlated with a decrease in C5a
receptors in the inflammatory cells. Conversely, intra-
articular injection of IFN exacerbated arthritis in the joint.5
This enhancement of arthritis could reflect the capacity
of IFN to activate the production of proinflammatory
cytokines such as IL-1 and TNF by monocytes already
recruited into the synovial tissue. Furthermore, the effects
of IFN in the treatment of rheumatic disease are con-
sidered ambiguous.6–8 In one double-blind, controlled
study of 91 patients with rheumatoid arthritis,6 a statistically
significant improvement in clinical disease among the
recombinant IFN-treated patients was reported. In two
other studies,7,9 which included 26 and 105 patients
respectively, the IFN treated group showed someAddress correspondence to: Dr Y. Henrotin, Bone and Cartilage
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cant when compared with the placebo group.
Although IFN has primarily immunomodulatory as well
as antiviral and antiproliferative properties, a number of
recent studies has shown that IFN is also able to modulate
the metabolism of connective tissue cells. IFN induces the
production of reactive oxygen species and PGE210–12 and
the expression of ICAM-1 and major histocompatibility
complex class II antigens by human isolated chondrocytes
and synovial fibroblasts.13–16 IFN also inhibits the syn-
thesis of cartilage-specific collagens, fibronectin and proteo-
glycans by chondrocytes.10,11,17,18 On the other hand,
IFN inhibits TNF and IL-1-induced collagenase and
stromelysin by chondrocytes, as well as IL-1 or TNF-
stimulated proteoglycan degradation in vitro.11,19 IFN has
both proliferative and antiproliferative effects on synovial
fibroblasts and stimulates chondrocyte proliferation. In
addition, IFN is a potent inhibitor of bone resorption. In
bone explants, it inhibits osteoclast differentiation,20 and
reduces the activity of existing cells in a manner similar to
calcitonin.21
These observations suggest that IFN could be involved
in cartilage degradation occurring in joint diseases, not only
by acting on cartilage itself but also on neighboring tissues.
Moreover, potent synergism and antagonism between
IL-1 and IFN have been reported with reference to their
actions on the metabolic function of chondrocytes. These
findings led us to hypothesize that IFN could be a modu-
lator of the IL-1 bioactivity. IL-1 modifies regulation of the
metabolic functions of chondrocyte, synovial and bone cells
leading to joint destruction.22,23 It stimulates metallopro-
teases and reactive oxygen species production by
chondrocytes and drastically inhibits cartilage matrix com-
ponent synthesis.24,25 Furthermore, it stimulates the pro-
liferation of fibroblasts and their production of type I
collagen and fibronectin. Moreover, IL-1 also induced the
production by fibroblasts and chondrocytes of soluble
mediators (e.g. IL-6, IL-8, NO, etc.) involved in the patho-
genesis of joint diseases.26,27 Some previous studies have
reported that the regulation of IL-1 production and activity
directly modulates cartilage resorption. IL-1 production is
inhibited by IL-4, IL-10 and IL-13 but stimulated by
TNF.28–30 IL-1-induced cartilage resorption is down-
regulated by two types of inhibitors: the IL-1 receptor
antagonist (IL-1ra) which competitively binds to the recep-
tor of IL-1 without inducing signal transduction and the
soluble receptors (IL-1sR), which bind IL-1 and diminish the
free concentration of soluble cytokines susceptible to bind-
ing the cell surface receptor. In vitro, IL-1-stimulating
effects on cartilage degradation are counterbalanced
by TGF and osteogenic protein 1 (OP1), and partially
reversed by NO synthase inhibitors.25,31–33
These findings prompted us to investigate the effect of
IFN on NO, IL-6, IL-8, IL-10, IL-1ra, PGE2, proteoglycans
and stromelysin production by normal non-stimulated and
IL-1-stimulated human chondrocytes. At the present time,
little is known about the regulatory functions of IFN on
chondrocytes, or about its role in the pathophysiology of
joint disease.
Materials and methods
HUMAN CHONDROCYTES IN CULTURE
Chondrocytes were cultured at high density for 48 h in
order to keep their phenotype. Cartilage was obtained fromthe knee of cadavers immediately after death via excision
from the superficial and medium layer avoiding the calcified
layer. Upon dissection, femoral and patellar articular sur-
faces were evaluated for gross pathological cartilage modi-
fications. Cartilage fragments were sequentially treated by
hyaluronidase (EC: 3.2.1.35; Sigma Chemie, Bornem,
Belgium) dissolved in Dulbecco’s modified Eagle’s medium
(DMEM, Biowhittaker, Brussels, Belgium) (0.5 mg/ml–3 g
of cartilage per 10 ml of enzyme solution) for 30 min at
37°C and under constant agitation (200 rpm). Cartilage
fragments were then put into pronase solution (1 mg/ ml in
DMEM-3 g of cartilage per 10 ml of enzymatic solution)
(EC: 3.4.24.4; Merck-Belgolabo, Overijse, Belgium) and
incubated with this enzyme for 1 h at 37°C, subsequently
re-incubated under constant agitation (200 rpm) with colla-
genase (EC: 3.4.24.3; Sigma Chemie) (1 mg/ml–3 g/10 ml
of enzyme solution) dissolved in DMEM containing 1% of
Ultroser (Gibco, Gent, Belgium) for 20 h at 37°C. The cells
were then filtered through nylon mesh with pore of 70 m,
washed three times, counted and re-suspended at 0.5 106
cells/ml of adequate culture medium. Nutrient medium was
DMEM without red phenol containing 2 mM of glutamine
and 1% of ITS+. ITS+ is a well-defined culture supplement
containing 0.625 mg/ml of insulin, 0.625 mg/ml of trans-
ferrin, 0.625 g/ml of selenium acid, 125 mg/ml of bovine
serum albumin (BSA) and 0.530 mg/ml of linoleic acid.
Cells were kept in this culture medium for 48 h to eliminate
in-vivo contamination with drugs. After this washout period,
cells were seeded into 24-well plates and maintained in
culture for 48 h at 37°C in a 95%–5% oxygen–CO2 environ-
ment. Cells and supernatant were separated by centrifug-
ation (160 g; 5 min). The cells recovered after collagenase
digestion of the tissue were 95% viable as demonstrated by
the vital stain with trypan blue. Cell pellets were washed
twice with HBSS (Hank’s buffer saline solution, Gibco,
Merelbeke, Belgium) and then homogenized in phosphate
buffer saline (PBS) pH 7.5 by ultrasonic dissociation (10 s
pulses, power 50 W/cm2). Culture media were directly
assayed for NO, IL-6, IL-8, IL-10, prostaglandin E2 (PGE2),
stromelysin, proteoglycan (PG) and IL-1ra. All the chemi-
cals for which the source was not mentioned were of the
purest grade available commercially.
CULTURE TREATMENT
Human normal chondrocytes (±0.5 106 cells/ml) were
cultured for 48 h in the absence or in the presence of
human recombinant IFN (rhIFN, Roche, Brussels,
Belgium) (0–100 U corresponding to 0.05–5 ng/ml) added
solely or in combination with interleukin-1 (IL-1;
2.10−10 M, Roche, Brussels, Belgium) and/or NG-mono-
methyl-L-arginine (L-NMMA; 0.5 mM). Four culture flasks
were used for each concentration of cytokines as well as for
the corresponding control. Each culture was run with
chondrocytes from the knee joint of a single patient. Each
culture condition was tested at least three times with
cartilage samples coming from three different young
(<35 years) donors. Cell viability was superior to 95% in all
culture treatments.
PROTEOGLYCAN (PG) RADIOIMMUNOASSAY
PG released into culture medium was assayed as
described previously.34 Briefly, human cartilage PG was
extracted according to the methods of Roughley et al.35
476 Y. E. Henrotin et al.: In vitro effects of IFN on chondrocytesand Bayliss and Venn.36 Antiserum against human carti-
lage PG was raised in rabbits according to the method of
Vaitukaitis et al.37 Antibodies were directed against the
core protein of human cartilage PG. No cross-reaction was
observed with glycosaminoglycans such as chondroitin
sulfate or keratan sulfate nor with PG treated with various
proteases. Only treatment with proteolytic enzymes
(papain, trypsin and chymotrypsin) abolished or diminished
immunoreactivity as opposed to treatment with chondroiti-
nase ABC and neuraminidase. Antiserum did not cross-
react with other cartilage matrix constituents such as type
II, type IX, and type XI collagens. The lack of cross-reaction
with bone PG or skin, cornea, liver, heart or lung tissue
extracts, showed that the antiserum used in the study
contains only specific aggrecan antibodies.
The analytical sensitivity of the RIA was 0.6 ng/tube. The
intra- and interassay coefficients of variation were <10 and
20%, respectively, for the linear part of the curve.
IMMUNOASSAY FOR STROMELYSIN
Total stromelysin production was assayed using a EASIA
(enzyme amplified sensitivity immunoassay) provided from
Biosource Europe (Nivelles, Belgium). In this immuno-
assay, monoclonal antibodies are directed against pro-
stromelysin, activated-stromelysin and stromelysin bound
to TIMP-1 and TIMP-2. Antibodies do not cross-react with
stromelysin bound with 2-macroglobulin, collagenase
or gelatinase. The method was linear between 5 and
20 ng/ml, with a limit of detection of 2.5 ng/ml.
NO ASSAY
Nitrite is a stable end product of nitric oxide. Nitrite
concentrations in conditioned media were determined by a
spectrophotometric method based upon the Griess reac-
tion.38 Briefly, 200 l of supernatant was added to 50 l 6.5
M HCL and 50 l 37.5 mM sulfanilic acid. After 10 min at
room temperature, 50 l of 12.5 mM N-(1-naphtyl)-ethylene
diamine (Merck, Darmstadt, Germany) was added. The
absorption was measured at 540 nm. Sodium nitrite
(NaNO2) was used for calibration.
PGE2 RADIOIMMUNOASSAY
PGE2 was assayed in conditioned culture medium with-
out extraction according to a previously described radio-
immunoassay (RIA).39 Polyclonal antiserum, obtained from
rabbit, did not cross-react with other prostanoids (TxB2,
6-keto-PGF-1, PGA2) or with fatty acids (arachidonic,
linoleic, oleic acids). Intra- and interassay coefficients of
variation are 6 and 10%, respectively. The recovery of
known amounts of PGE2 added to the culture medium was
satisfactory (90–97% for the amounts of PGE2 ranging
from 2500 to 312 pg/ml). The limit of detection of the RIA
was 20 pg/ml.
IMMUNOASSAYS FOR CYTOKINES AND IL-1 RECEPTOR
ANTAGONIST
IL-6, IL-8, IL-10 and IL1-ra released by chondrocytes in
the culture media were assayed by four EASIA (Cytosets)
designed by Biosource Europe (Nivelles, Belgium). The
assays were based on the oligonal system in which severalmonoclonal antibodies were directed against distinct
epitopes of the cytokines.
DNA ASSAY
Chondrocyte DNA content was measured according to
the fluorimetric method of Labarca and Paigen.40
STATISTICAL ANALYSIS
The results (mean±S.D.) were expressed per g of DNA
for proteoglycan, stromelysin, IL-1ra, PGE2, cytokines and
NO measured in the culture medium. Comparison of mean
values was performed for each culture individually using
the unpaired Student’s t-test with a limit of significance at
P<0.05. Multiple comparisons between treated groups
were also achieved by analysis of variance test. Corre-
lations between the variables were investigated by linear
regression analysis and one-way analysis of variance was
performed (F-test).
Results
EFFECTS OF IFN ON NON-STIMULATED NORMAL CHONDROCYTES
The effects of IFN were investigated on human
chondrocytes isolated from young cartilage at concen-
trations ranged between 0.1 to 100 units/ml. These concen-
trations corresponded to the levels of IFN found in the
synovial fluid of patients with OA or RA (values between 0.6
and 23.7 U/ml;1,2. As shown in Fig. 1, IFN at concen-
trations of 1, 10 and 100 U/ml significantly stimulated NO
production (0.05<P<0.001). Furthermore, IFN dose-
dependently increased IL-6, IL-1ra and PGE2 production(R=0.85−0.95; P<0.001) but strongly inhibited IL-8. IL-8
production was depressed by 25 and 55% at the IFN
concentrations of 10 and 100 U/ml, respectively. On the
other hand, PG production was dose-dependently inhibited
by IFN (R=0.82; P<0.01) whereas stromelysin was
slightly but significantly decreased by IFN only at
the highest concentration of 100 U/ml (P=0.02). IL-10
was undetectable in non-stimulated human chondrocyte
cultures.
EFFECTS OF IFN ON IL-1-STIMULATED HUMAN CHONDROCYTES
As previously reported,26,27 IL-1 at the concentration of
2.10−10 M significantly stimulated NO, IL-6, IL-8, PGE2,
IL-10, IL-1ra and stromelysin production but drastically
depressed PG synthesis (P<0.05, Table I). Addition of
rhIFN at the concentrations of 10 and 100 U/ml signifi-
cantly increased IL-1-stimulated NO, IL-6 and IL-1ra pro-
duction but strongly depressed the stimulatory effect of
IL-1 on IL-8 and IL-10 productions, whereas IL-1-
induced stromelysin production was inhibited at the con-
centrations of 1, 10 and 100 U/ml of IFN. Finally, IFN
acted synergically with IL-1 to depress PG production by
human chondrocytes but did not significantly modify IL-1-
stimulated PGE2 production (Table I).
ROLE OF NO IN CHONDROCYTE RESPONSES TO IFN
To evaluate the role played by NO in the response of
chondrocytes to IFN, NO synthesis was blocked
Fig. 1. Effects of increasing doses of IFN on the production of NO, IL-6, IL-8, PGE2, IL-1ra, PG and stromelysin in the culture medium of
normal human chondrocytes (5.104 cells/ml). Data are the mean and S.D. of triplicate determinations and representative of three separate
experiments (total N=9).
Table I

















Controls 1.5±0.08a 0.22±0.04a 2.01±0.14a 47±7a 0.13±0.01a 14±2.3a 378±55a 1.3±0.1a
IL-1 2.10−10 M 2.9±0.09b 19±2b 97±7b 1401±244b 71±3b 124±5.2b 41±4b 2.8±0.1b
IL-1+IFN 0.1 U/ml 2.8±0.1b 18±1.5b 96±9.8b 1668±341b 62±3c 131±15b 34±3.8c 2.8±0.3b
IL-1+IFN 1 U/ml 3±2b 20.1±2.3b 97±8b 1731±160b 60±5c 174±30c 33±3.2c 1.8±0.3c
IL-1+IFN 10 U/ml 3.7±0.3 24±1.4c 81±11c 1454±280b 39±3c 254±20d 35±3c 1.3±1.0d
IL-1+IFN 100 u/ml 4.2±0.1c 29±5.3d 51±8d 1534±382b 23±1c 429±33e 32±5c 1.1±0.1d
Chondrocytes were treated or were not treated with IL-1 (2.10−10 M). Data are the mean and S.D. of triplicate determinations and
representative of three separate experiments. Letters indicate significant statistical differences between treatments. a≠b≠c≠d, with P<0.05
(Student’s t-test).
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competitive inhibitor of NO synthase.
Non-stimulated NO synthesis was significantly inhibited
by 0.5 mM of L-NMMA, whereas IL-1-induced NO syn-
thesis was reduced below the control value even in the
presence of high amount of IFN (Table II and Fig. 2). As
previously reported, addition of L-NMMA (0.5 mM) signifi-
cantly enhanced IL-6, IL-8 and PGE2 production over the
IL-1 production, suggesting that NO exerts a negative
feedback on PGE2, IL-6 and IL-8 synthesis by humanchondrocytes (Table II). Furthermore, here, we demon-
strated that L-NMMA did not modify the stimulatory effect of
IL-1 on IL-10, IL-1ra and stromelysin and did not affect the
IL-1-induced inhibition of PG production. However, the
inhibition of inducible NO synthase by L-NMMA significantly
reduced IFN-stimulated production of IL-6 and IL-1ra, but
did not modify the effects of IFN on IL-8, PG, PGE2 or
stromelysin (Fig. 2). In the presence of IL-1, addition of
L-NMMA, partially reversed the inhibitory effect of 10 and
100 U/ml of IFN on IL-10 and stromelysin (Fig. 3).
Table II

















Controls 1.5±0.08a 0.22±0.04a 2.01±0.14a 47±7a ND 14±2.3a 378±55a 1.3±0.1a
L-NMMA 0.5±0.05b 0.18±0.02a 1.94±0.22a 54±7a ND 14.3±2.3a 330±23a 1.4±0.11a
IL-1 2.9±0.06c 19±2c 97±7b 1401±244c 71±3a 124±5b 41±4c 2.8±0.08b
IL-1+L-NMMA 0.7±0.05b 25±2.1d 125±8c 5732±901d 72±1a 97±11c 44±0.6c 2.6±0.25b
Letters indicate significant statistical differences between treatments. a≠b≠c≠d, with P<0.05 (Student’s t-test).
Fig. 2. Production of NO, IL-6, IL-8, IL-10, IL-1ra, PG and stromelysin by human chondrocytes treated with rhIFN, in the presence (—C—)
or absence (—+—) of L-NMMA 0.5 mM. Results are the mean±S.D. values for four replicate wells and are representative of three similar
experiments. *=P<0.05; **=P<0.01 and ***=P<0.001 as compared with control.
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Joint diseases are characterized by synovial membrane
inflammation, cartilage degradation and subchondral bone
remodeling. Cartilage plays a central role in the pathophysi-
ology of joint diseases by producing a spectrum of soluble
mediators able to regulate its own metabolic functions in an
autocrine or paracrine manner as well as the metabolism of
neighboring tissues such as bone or synovium. Inversely,
chondrocyte functions are controlled by factors produced
by synovium and bone cells. Among these factors, IFN is
often described as a potent mediator of the cellular immune
reaction with potential regulatory actions on connective
tissues.41 Although IFN was not expressed in cartilage,42
IFN is found in OA and RA synovial membrane, suggest-
ing that this cytokine could influence cartilage metabolism.
In this work, we demonstrated that IFN synergized with
IL-1 to stimulate NO, IL-6 and IL-1ra and to inhibit proteo-glycans but antagonized the IL-1 stimulating effect on
IL-8, IL-10 and stromelysin production. These observations
were recorded at concentrations of IFN similar to those
found in the synovial fluid of patients with OA or RA.
In previous studies, similar opposite effects of IFN were
reported on synoviocytes from RA and OA patients.43
These observations assist in explaining that, relative to the
circumstances, IFN may have inflammatory or anti-
inflammatory activities. The antiinflammatory properties of
IFN could be related to its effects on IL-8 and IL-1ra. The
inhibition of IL-8 by IFN may lead not only to a reduction of
the number of neutrophils and T-lymphocytes invading the
joint cavity but also a decrease of neovascularization of
the synovial membrane, as suggested by a recent paper on
the properties of IL-8 as an angiogenic factor.44 On the
other hand, we have shown that IFN was a potent stimu-
lator of IL-1ra synthesis by chondrocytes. IL-1ra is a
Fig. 3. Effects of increased amounts of IFN on NO, IL-6, IL-8, IL-10 and stromelysin synthesis by IL-1-treated (2×10−10 M) human
chondrocytes cultured for 48 h with (—C—) or without (—+—) L-NMMA 0.5 mM. Results are expressed as the mean±S.D. values for four
replicate wells and are representative of three similar experiments. *=P<0.05; **=P<0.01; ***=P<0.001 compared with the control.
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observed during the pathological process of OA and RA,
including prostaglandin synthesis by synovial cells, colla-
genase production by chondrocytes and cartilage matrix
degradation.45–49 Treatment of rats with IL-1ra can signifi-
cantly suppress recurrence of swelling and severity of
synoviotis and erosion induced by re-activation by i.v.
injection of PG-APS (peptidoglycan-polysaccharide iso-
lated from the cell wall of group A streptococci).49 Further-
more, intraarticular injection of IL-1ra also prevents
cartilage lesion appearance in rabbit OA model.51 There-
fore, our study provides novel mechanistic data to explain
the antiinflammatory properties of IFN.
On the other hand, IFN can also inhibit IL-10 production
by IL-1-stimulated human chondrocytes. In vitro, IL-10 is a
cytokine with the capacity to down-regulate the synthesis
of proinflammatory cytokines (IL-1 and TNF) by mono-
nuclear cells51 and completely reverse inhibition of carti-
lage PG synthesis induced by stimulated RA mononuclear
cells.53 However, the role of this antiinflammatory cytokine
in the pathogenesis of erosive joint diseases is not yet
clearly demonstrated.We also demonstrated that IFN may interfere with
cartilage metabolism by inhibiting PG and stromelysin
production. Our results are consistent with those found in
the literature.10,11,17,53,54 Destruction of cartilage in ar-
thritis is partially attributable to metalloproteases released
by the chondrocytes in response to IL-1. Here, we demon-
strated that IFN counteracts the stimulating effect of IL-1
on stromelysin synthesis suggesting that IFN could modu-
late the progression of tissue degradation and remodeling
in inflammatory conditions as observed in RA. Further-
more, it appeared that IFN inhibited PG synthesis at a
concentration 100 times lower than the concentration
required to inhibit stromelysin. This latter observation sug-
gests that IFN could have different effects on cartilage
metabolism according to its relative concentration which
may vary during the course of the disease and at different
sites within the joint. In addition, Quintavalla et al.53 have
demonstrated that subpopulations of chondrocytes within
the joint may differ in their responsiveness to cytokines,
including IFN. Collectively, these observations could
explain some events occurring in joint diseases such as
OA. During OA development, phases of destruction and
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disease, IFN contributes to repair reaction failure by
inhibiting PG synthesis and has a protective role limiting
cartilage degradation by metalloproteinases in inflamma-
tory conditions. This hypothesis is supported by other work
demonstrating that IFN partially counteracts the IL-1-
induced cartilage degradation as measured by gly-
cosaminoglycan released from cartilage fragments in
culture, but acts synergically with TNF to inhibit cartilage-
specific type II, IX and XI collagens production by fetal and
adult human chondrocytes.10,11 The effects of IFN do not
appear to be due to cell death or proliferation. No decrease
in cell viability, as determinated by trypan blue exclusion,
was evident in culture of chondrocytes incubated with up to
100 U/ml of IFN (data not shown) and DNA levels
remained stable regardless of the concentrations of IFN
employed.
Interestingly, we have observed that IFN stimulated NO
production by chondrocytes, suggesting that several effects
of IFN could be mediated by NO. To verify this hypothesis,
L-NMMA, a NO synthase inhibitor, was added to the
chondrocyte cultures. As previously described, we have
observed that the inhibition of endogenously NO production
resulted in a significant enhancement of the IL-1-
stimulated IL-6, IL-8, and PGE2, suggesting that NO down-
regulates the synthesis of some inflammatory mediators.27
Inversely, the effects of IFN on IL-8 and PGE2 synthesis,
were not significantly affected by NO synthase inhibition
whereas its stimulating effect on IL-6 and IL-1ra production
was partially reversed. These data clearly show that IFN
and IL-1 activate different signaling pathways in which NO
plays different regulatory functions. On the other hand,
neither IL-1 nor IFN effects on stromelysin and PG
production were significantly modified by the addition of
L-NMMA. These results differ from studies showing that
L-NMMA partially reversed the effect of IL-1 on the syn-
thesis of cartilage matrix molecules and on MMP
activity.33,56,57 This discrepancy can be explained by the
difference in methodology. In our study, newly synthesized
proteoglycans were quantified by RIA using an antiserum
directed against the core protein of the aggrecans, whereas
other studies revealed proteoglycans synthesis by the
incorporation of 35SO4 into glycosaminoglycans.55,56 In our
work, we have quantified stromelysin by an immunoassay
in which monoclonal antibodies were directed against pros-
tromelysin, activated-stromelysin and stromelysin bound
with TIMP-1 and TIMP-2. In other studies, metalloprotease
activity was measured by enzymatic assay using labeled
substracts. Metalloprotease activity is the result of the
efficiency of both activation and inhibition systems and not
only the result of the enzyme synthesis.
In conclusion, these results show that IFN has a
number of effects on articular chondrocytes in vitro and
suggest that IFN may modulate joint inflammation by
modulating mediator production by chondrocytes. More-
over, we clearly show that the role played by IFN in joint
disease pathophysiopathology may differ according to its
own concentration but also to the concentration of other
cytokines such as IL-1.
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